951655-67-7Relevant articles and documents
2-Aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors
Mahboobi, Siavosh,Sellmer, Andreas,H?cher, Heymo,Garhammer, Christian,Pongratz, Herwig,Maier, Thomas,Ciossek, Thomas,Beckers, Thomas
, p. 4405 - 4418 (2008/02/13)
Histone deacetylase (HDAC) inhibitors are considered to be drugs for targeted cancer therapy and second-generation HDIs are currently being tested in clinical trials. Here, we report on the synthesis and biological evaluation of a novel HDAC inhibitor sca